steve,
By the Dec. CC they will be through the 1st cohort, and I assume will be well into the 2nd, (possibly starting the 3rd) - depends on how long they have to progress through a dose level/cohort before starting the next one...
Perhaps we'll simply hear something general saying it was safe in patients treated to date, (it is a safety trial after all), and they've added a new site, etc.
Perhaps they'll mention in general that it's showing signs of efficacy.
Perhaps they'll mention some specific numbers, but remember this is a dose escalation trial, and we don't know the dose levels per cohort. Hopefully (probably) they'll be starting at 0.3 and what do you expect from that dose? - safe.
Who knows. We'll see.
j
News 
Market Data 
Discover 
AI
